Sanofi and Johnson & Johnson reached a partnership to assist in the production of a new crown pneumonia vaccine

CompilationFan Dongdong

After the vaccine giant Sanofi suffered a setback in the mid-term development of the new crown pneumonia vaccine, the company did not give up hope of the new crown pneumonia vaccine.

On Monday, Sanofi announced that it has established a production partnership with Johnson & Johnson to produce a vaccine for the new crown pneumonia of the Johnson & Johnson adenovirus vector in Europe.

After Johnson & Johnson's new crown pneumonia vaccine is approved, Sanofi will use its factory in Massai Tour, France to assist Johnson & Johnson in the production of the vaccine.

It is worth mentioning that according to Johnson & Johnson's recent release of the latest test data, the vaccine is sufficient to prevent the new coronavirus after 1 dose.

Johnson & Johnson has previously completed a large-scale Phase 3 vaccine trial and submitted relevant data results to regulatory agencies in the United States and Europe.

At the end of last year, Sanofi had to postpone vaccine development due to unsatisfactory test progress.

The urgency of the COVID-19 pandemic and the shortage of supply capacity have spawned numerous partnerships among large pharmaceutical companies, and former competitors have turned into collaborative alliances.

Although Sanofi’s top priority is to advance Sanofi’s own two COVID-19 vaccine trials, Sanofi recognizes that Pfizer, BioNTech, and Johnson & Johnson face the challenge of insufficient supply in vaccine production.

Also on Monday, Sanofi and GlaxoSmithKline announced the resumption of new crown vaccine testing.

In the early stages of vaccine development, it is generally believed that Sanofi, GlaxoSmithKline and another top vaccine giant Merck will play an important role in global immunization work, but the actual progress of these companies is far lower than expected.

Reference source:

1.

2.